Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramesh Konduru

Internal Medicine Raleigh, NC Medical Doctor

NPI 1477717445 CMS profile 575911

10640 Durant Rd Ste 101, Raleigh, NC 27614

Open in the dashboard

General payments

$6,562

401 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramesh Konduru of Raleigh, NC is reported in the CMS Open Payments database as having received $6,562 across 401 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $904 43
2024 General $1,281 62
2023 General $1,033 60
2022 General $897 56
2021 General $1,000 72
2020 General $675 43
2019 General $773 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramesh Konduru
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ramesh Konduru were reported at $904. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ramesh Konduru Internal Medicine median Middle half National median
2019 $773 $159 $48–$570 $163
2020 $675 $119 $33–$402 $114
2021 $1,000 $135 $37–$521 $132
2022 $897 $141 $42–$496 $149
2023 $1,033 $149 $45–$519 $160
2024 $1,281 $154 $47–$537 $164
2025 $904 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,805 117 payments
  2. AstraZeneca Pharmaceuticals LP $661 33 payments
  3. GlaxoSmithKline, LLC. $516 36 payments
  4. AbbVie, Inc. $453 30 payments
  5. Amarin Pharma Inc. $264 18 payments
  6. Amgen Inc. $254 27 payments
  7. Pfizer Inc. $227 14 payments
  8. Lilly USA, LLC $223 13 payments
  9. Abbott Laboratories $186 7 payments
  10. ITI, Inc. $143 8 payments
  11. Other $1,830 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,562 401 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,336 88 payments
  2. RYBELSUS $1,108 73 payments
  3. TRELEGY ELLIPTA $455 33 payments
  4. FARXIGA $345 20 payments
  5. Repatha $252 26 payments
  6. BREZTRI $243 5 payments
  7. Wegovy $232 15 payments
  8. Vascepa $183 13 payments
  9. VRAYLAR $176 13 payments
  10. UBRELVY $150 9 payments
  11. Other $3,718 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 274 drugs

Part D claims

27,678

Median for Geriatric Medicine: 2,306

Drug cost

$1,917,520

Median for Geriatric Medicine: $150,713

Branded share of claims

21.1%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 873 $352,524
Januvia Sitagliptin Phosphate Brand 212 $114,372
Jardiance Empagliflozin Brand 163 $91,979
Ozempic Semaglutide Brand 48 $69,603
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 13 $57,660
Linzess Linaclotide Brand 101 $50,308
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $47,556
Farxiga Dapagliflozin Propanediol Brand 154 $45,012
Invega Sustenna Paliperidone Palmitate Brand 17 $43,872
Tradjenta Linagliptin Brand 111 $43,258

The 10 drugs with the highest cost, of 274 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$221,405

Of which drugs: $332

Medicare patients

507

Average age 74

Services billed

4,949

263 women, 244 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 38%
Depression 37%
Alzheimer's or dementia 36%
Ischemic heart disease 30%
Chronic kidney disease 28%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 1,861 $190

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $153
$153 39 —
Wegovy
  • Novo Nordisk Inc $120
$120 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $86
$86 61 —
Auvelity
  • Axsome Therapeutics, Inc. $83
$83 — —
RYBELSUS
  • Novo Nordisk Inc $78
$78 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

401 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record